Bill · H.R. 10150· House(119-HR-10150)
Advancing Botanical Drug Development Act of 2026
- Introduced
- 8/27/2026
- Last activity
- 8/27/2026 — Referred to the House Committee on Energy and Commerce.
- Sponsored by
- Lauren Boebert
- Cosponsors
- - 1 - 0
- Introduced
- In Committee
What this bill would do
This bill, known as the "Advancing Botanical Drug Development Act of 2026," aims to amend the Federal Food, Drug, and Cosmetic Act. It proposes providing a specific period of market exclusivity for botanical drugs. The legislation seeks to address the unique scientific and manufacturing challenges associated with plant-derived raw materials. By creating these incentives, the bill intends to encourage private investment in the research and development of these therapies. The goal is to increase treatment options for chronic and age-related diseases.
Yes· 3 of 8
Would people over 65 be better off under this?+4
The bill specifically targets chronic and age-related diseases which frequently affect seniors.
Would retired people be better off under this?+4
The focus on age-related diseases provides potential health benefits for retirees.
Does this make health care easier to get in general?+4
By incentivizing botanical drug development, the bill seeks to increase treatment options for patients with chronic diseases.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Increased Treatment Options: Expanding incentives may increase multi-target treatment options for patients suffering from multi-pathway, chronic, and age-related diseases (Section 2, Finding 8).
-
Market Exclusivity for Botanical Drugs: A botanical drug approved under specific criteria would be entitled to a 12-year period where certain other applications cannot become effective (Section 3).
-
Encouraging Innovation: The bill suggests that providing tailored periods of regulatory exclusivity can encourage innovation and facilitate long-term investment in research and development (Section 2, Finding 7).
Potential Negative Impacts for People
- Increased Development Burdens: The development of botanical drugs involves unique scientific and manufacturing challenges, such as the need for extensive sourcing controls and consistency testing, which may increase costs (Section 2, Finding 5).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Retirees+4Good For Seniors+4Good For Business Owners+3Good For People With Disabilities+2
- Healthcare
- Improves Healthcare Access+4
- Economy And Finance
- Improves Economic Growth+3
- Education And Technology
- Improves Intellectual Property Fairness+2
- Governance And Ideology
- Increases Federal Power+1
- 8/27/2026
- Referred to the House Committee on Energy and Commerce.
- 1 Cosponsor added.
- Introduced in House
Derrick Van OrdenRepublican · Wisconsin